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A B S T R A C T
Background
Although incidence of dementia is known to vary between nations, variation within country
has not been explored because most incidence studies are single site or have insufficient
numbers to compare sites. Few countries have conducted multisite incidence studies in order
to facilitate national comparisons. This study aims to provide robust measures of the variation
of the incidence of dementia across sites within England and Wales and produce overall
estimates by age and sex.
Methods and Findings
The Medical Research Council Cognitive Function and Ageing Study used identical
methodology in five diverse sites across the United Kingdom, each with different risk patterns
and mortality rates. Incidence has been estimated using likelihood-based methods between the
first two waves of interviews. Incidence rates rise with age, particularly above the age of 75 y,
from 7.4 (95% confidence interval, 3.6–16.1) per 1,000 person years at age 65–69 y to 84.9 (95%
confidence interval, 63.0–107.8) per 1,000 person years at age 85 y and above. The rate of
increase for both sexes is marked, and continues into the oldest age groups. Hence, it is
estimated that approximately 180,000 new cases of dementia occur in England and Wales each
year. There is no convincing evidence of variation across sites, and incidence rates do not reflect
the variations in the prevalence of possible risk factors in these sites.
Conclusion
There is no evidence, within England and Wales, of variation in dementia incidence across
sites. Dementia incidence rates do not tail off at the oldest ages.
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Introduction
Dementia remains an incurable condition of major signiﬁ-
cance to the world’s ageing populations. There have been
numerous studies of the prevalence, incidence and natural
history of dementia though there have been very few which
compare diverse locations. Most studies are based on a single
site (e.g., Rotterdam, The Netherlands [1], Framingham,
Massachusetts, United States [2], East Boston, Massachusetts,
United States [3], and Cache County, Utah, United States [4])
or take small population samples from multiple sites (the
Canadian Study of Health and Aging [5] and the Italian
Longitudinal Study on Aging [6]). Incidence studies of
dementia are particularly valuable for less-biased comparison
of disease occurrence, pointing to aetiological investigation,
as well as being essential for policymakers. Comparisons of
incidence estimates are hampered by any variation in
methodology. Despite this, researchers frequently attempt to
assess whether rates in a given study are similar to those
provided elsewhere [7]. Although such estimates, on the whole,
seem reasonably consistent across the more developed regions
of the world, there have been widely divergent estimates
reported within the United States (East Boston study [3] versus
Chicago, Illinois [8], in which the disorder deﬁnition is
different, but even between Framingham [2] and the Northern
Manhattan [New York] Aging Project [9] in which the disease
criteria are identical.) These variations have been dismissed as
being due to the variation in methodology, which may be true,
but without identical methodology, this cannot be known.
There are substantial differences in possible risk factors for
dementia within the developed world. Such chronic disease
risk factor variation is thought to be responsible for the wide
variation seen in other diseases of older age such as cancer
and cardiovascular disease (e.g., differences between North
and South Europe). The only systematic examinations across
sites with identical methodology and sufﬁcient numbers for
comparison are between two less-developed regions and the
United States: the Ibadan, Nigeria–Indianapolis, Indiana,
United States study [10] and the rural India–United States
study [11]. These did show substantial differences across sites,
which indicate that variation, if large, can be detected. No
such similar exercise has been conducted within countries
with diverse risk patterns. Given the available evidence on
vascular risk factors for dementia, strengthened by the
published single site longitudinal studies, and the marked
variation in vascular risk across Europe and within European
sites [12], there could be parallel variation in the incidence of
dementia. The whole thrust of the prevention of vascular risk
for dementia (e.g., Forette et al. [13]) is based on the premise
that dementia incidence could be reduced if vascular risk
were better controlled. It is reasonable therefore to compare
sites with known variable vascular risk to assess whether there
is variation in the incidence of dementia. Previously we have
shown that areas across England and Wales vary considerably
with regards to their vascular risk patterns [14]. Cardiovas-
cular risks varied by centre from high values in Newcastle,
England, and Gwynedd, Wales (angina 16%, intermittent
claudication 4%, heart attacks 12%, and stroke 8%) to low
prevalence in Cambridgeshire and Oxford, England (angina
11%, intermittent claudication 2%, heart attacks 9%, and
stroke 6%). Nottingham, England, generally lies in between,
however it shows a high stroke rate (8%) and low intermittent
claudication rate (0.5%).
Whether or not there is variation in the incidence of
dementia across sites, it is of particular importance for policy
to understand the occurrence and natural history of
dementia in the over 80-y-olds. This is the population group
expanding at the greatest rate at present. In the United
Kingdom over the past decades, a number of small ﬁeld-based
studies have reported incidence in the very old (e.g., the
Cambridge City over 75 cohort [15,16], Melton Mowbray [17],
and Gospel Oak [18,19]). The limited number of respondents
in each of these single centre studies in the oldest age groups
has hampered the examination of incidence in these groups.
Those estimates available in the published literature are
based on combined analyses of diverse studies [20].
The Medical Research Council Cognitive Function and
Ageing Study (MRC CFAS) is a multi-site study in the United
Kingdom and has already published ﬁndings on the preva-
lence of dementia across six sites [21]. No systematic differ-
ences were found across the ﬁve identical sites within the
study. It is known that there is considerable variation in
mortality across the country and in the sites that are
represented in this study [22–24]. Thus the absence of
variation in prevalence could be masking an increased
incidence allied to an increased mortality in the northern
sites. This can only be investigated through longitudinal
studies. Here we present data from the 2-y follow-up of the
baseline population, to compare incidence estimates of
dementia across ﬁve methodologically identical sites with
widely differing risk proﬁles.
One of the sites, the Liverpool centre, was funded earlier and
had a slightly different design; the Liverpool incidence study is
described in detail elsewhere and not included further here [25].
Methods
MRC CFAS is a population-based study of individuals aged
65 y and over living in the community, including in
institutions; it has a two-phase two-wave design, with the
waves 2 y apart. Ethical approval for the study was obtained in
each site. The prevalence results have already been discussed
in detail [21]. Two sites were rural—Cambridgeshire and
North Wales (Gwynedd)—and three urban—Nottingham,
Newcastle, and Oxford. These were selected both for known
possible chronic disease risk factors–the north has high
vascular risk load—and for epidemiological expertise in
conducting population-based research.
Baseline Sample
The population sample was drawn from the Family Health
Service Authorities lists covering speciﬁc geographically
deﬁned areas. These are population-based registers of the
general practitioners, which provide nearly complete popula-
tion enumeration including in institutions. Random selection
was carried out to recruit at least 1,250 individuals in each
centre in each of the age groups 65 to 74 y and 75 y and above.
Population sampling levels varied from 1 in 2.4 individuals in
Cambridgeshire in the older age group, to 1 in 14 in Newcastle.
The Approach and Sequence of Interviews Relevant to
Calculation of Incidence
Individuals selected for the study were approached either
through an introductory letter from their general practi-
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tioners or from the local principal investigator with a follow-
up visit or telephone call to seek permission to visit and
explain the study. Those who agreed to participate were
asked for informed consent before proceeding to interview.
When an individual was unable to give informed consent, a
proxy (relative or caregiver) was approached. The ﬁrst
interview was a screening interview, which was followed by
a more intensive assessment of a subsample of the study
population. After 2 y a re-screen of individuals who were not
selected for assessment at baseline was undertaken, followed
by a selection of a further assessment sample. Those who had
been previously assessed were interviewed with a combined
screen and assessment interview. The study design to the end
of wave 2 is shown in Figure 1. Further interviews with
informants, interim interviews, and interviews after 2 y have
been undertaken but are not used in the analysis presented
here.
The Interviewers
Baseline and incidence screen. Interviewers were recruited
locally for each site, with a range of ages and backgrounds,
mainly professions allied to medicine. They were all trained
in interviewing and the computer skills necessary for
administration of the computerised interview. The local
interviewers were trained by local coordinators who had been
trained by the national coordinator to ensure consistency.
Repeat interviewing was not carried out. Monitoring of the
quality of interviews with feedback was undertaken through-
out the study. Intermittent audio taping of interviews, with all
local interviewers meeting regularly to listen and rate each
others’ tapes, was carried out to ensure continuing compa-
rability across sites. The national coordinator visited all sites
regularly.
Baseline and incidence assessment/combined screen assess-
ment. Interviewers were recruited locally and nationally for
each site, and included psychologists, psychiatrists, registered
nurses, and others with similar backgrounds, all trained by
the National Coordinator. Interviewers regularly audiotaped
interviews for quality checks and took part in between-centre
meetings with joint rating and discussion of discrepancies
during the study period to ensure comparability across sites.
The Interviews
Prevalence screen [19.12.1990 to 13.6.1994]. The prevalence
screen interview (S0) lasted an hour and contained basic
information on residence, marital status, social class, and
main occupation during working life [26]; social and service
contacts [27]; physical health and well-being, including
vascular risk factors [28,29]; activities of daily living as
measured by the Townsend scale [30,31]; organicity items
from the Geriatric Mental State, a standardised psychiatric
interview designed to detect dementia, depression, and other
mental illness in the older population, to which an
algorithmic programme (AGECAT [Automated Geriatric
Examination Computer Assisted Taxonomy]) is applied to
create a diagnosis, including items for the organicity scale
(O0 to O5, with O3 and above indicating dementia) [32];
Mini-Mental State Examination (MMSE) with additional items
[33,34]; and regular medication (prescribed and over the
counter).
Prevalence Assessment [26.2.1991 to 21.9.1994] Undertaken
in approximately 20% of those in S0, the prevalence
assessment interview (A0) has a clinically based content and
is built on the Geriatric Mental State (GMS) version B3, which
focuses on dementia and depression [32]. It allows for the
generation of the dementia measure of the study—the case-
level organicity status (O3 and above, with incorporation of
the other diagnostic algorithms to take into account
comorbidity such as depression and anxiety).
Incidence screen [22.2.1993 to 16.7.1996]. After 2 y,
respondents who were not previously assessed were ap-
proached for re-interview. The incidence screen interview
(S2) was substantially the same as S0, with the omission of
stable items, such as earlier occupation, and with modiﬁca-
tion of physical health measures to collect information on
new events since the last interview.
Incidence assessment [28.6.1993 to 29.7.1996]. The inci-
dence assessment interview (A2) followed on in a 20%
selected sample from S2 and was the same as A0.
Combined screen assessment [13.4.1993 to 25.7.1996]. All
individuals who had previously been assessed were ap-
proached for a combined screen and assessment (C2). This
was a merged interview with collection of key variables from
the screen, change in physical health, and activities of daily
living, along with the diagnostic component of the assessment
interview.
Priority mode. Interviewers at theS0 and S2 stages were
instructed to complete interviews whenever possible, but
when individuals were unable to answer the ﬁrst few
questions accurately (due to disorientation in time and
Figure 1. Flow Chart of Individuals Contributing to the Incidence
Analysis
D indicates died between waves, R indicates refused, and M indicates
moved away from the study areas between waves.
DOI: 10.1371/journal.pmed.0020193.g001
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space), there was a systematic skip such that the interview was
truncated to a small set of priority questions that included
the organicity items of the GMS [32] and the MMSE [33].
Interviewers were also able to select the priority mode if they
felt the interview was jeopardised and a complete interview
would be impossible.
Selection for Assessment
Four of the sites used identical sampling fractions from the
screening interview data for assessment at prevalence (shown
below). In Cambridge, the density was reduced after
approximately one year due to higher numbers of the sample
population eligible for assessment. The sampling fractions
varied by age at screen and cognitive ability at that interview.
These sampling fractions were programmed into the inter-
view. The sampling groups were age group (65–74 y or 75 y
and above), ability group (AGECAT O3þ; AGECAT O0–O2
and MMSE less than 21 or missing; AGECAT O0–O2 and
MMSE 21–25; and AGECAT O0–O2 and MMSE 26–30). The
sampling groups for selection to the incidence assessment
were similar, modiﬁed slightly based on experience, with
different sampling fractions and with the ability group
calculated at the incidence screen. There was a change in
the sampling fractions during the second-wave selection
process because too many were being selected for assessment;
this change was programmed into the software with a version
label. The whole scoring spectrum was eligible for selection to
assessment at both waves with theoretical sampling fractions
varying from 1:1 to 1:15 at both waves. The exact weights can
be found on the MRC CFAS website (http://www-cfas.
medschl.cam.ac.uk/data_and_analysis.htm#Weights). For
analysis, empirical weights have been used as these have been
shown to be more robust [35].
Flagging
The whole sample was ﬂagged at the National Health
Service Central Register, which collects all death registrations
from England and Wales. Quarterly updates of the vital status
of participants were therefore possible, not just those seen at
follow-up.
Study Diagnosis
Diagnosis was based on the GMS B3 organicity case level
generated by AGECAT as described above, equivalent to
Diagnostic and Statistical Manual of Mental Disorders, Third Edition,
Revised diagnoses [32,36]. The interviews used in the study
were modiﬁed to provide a more structured interview onto
which the algorithms to produce AGECAT diagnoses were
mapped. AGECAT categorised individuals on an ordinal scale
for O0 to O5 where O0 indicates no organic symptoms, O1–
O2 indicate subclinical symptoms, and O3–O5 indicate case-
level organic diagnosis. These were applied to the assessed
sample at both the prevalence and incidence phases. All the
records available from individuals unable to complete the full
interview (n¼ 23, eight with dementia) including a structured
vignette from interviewers, informant information, and
interviewers’ standardised observations were reviewed clin-
ically and a clinical judgement made. Most of these cases were
individuals with severe prevalent dementia, living in institu-
tions for whom such limited information was available that
there was insufﬁcient data to run the algorithms (none of
these [n ¼ 18] actually survived to be in this analysis and are
not included above). Any individuals who recovered from
dementia (indicating an inaccurate diagnosis at one time
point) were additionally checked for their true diagnosis
status using interim interviews and the same information
used above, as were all individuals suspected of having
dementia, but with high MMSE scores (n ¼ 7).
Statistical Methods
Version 6.2 of the data was used for this analysis. Analysis
has been undertaken using Stata version 7.0 [37].
Centre analysis. The study power calculations were based
on overall centre estimates, not centre, age, and sex, because
sample sizes would need to be much greater for such
comparison. A single age-standardised incidence rate by
centre is provided referenced to the 1991 age population of
England and Wales [22].
Incidence rate calculation. Due to the complex nature of
the design, individuals were included in the assessment phases
on the basis of stratiﬁed random sampling that used the
following factors: interview version, age group, and ability
group (as detailed previously). Calculation of the incidence
rate in two-phase studies is complicated by individuals in the
incidence assessment interview (A2) having unknown preva-
lence diagnosis, unless a sensitivity of 100% at sampling is
assumed. This assumption is not plausible in MRC CFAS
because the cognitive threshold for 100% selection was quite
low. The analysis presented here does not assume that the
screening instruments are 100% sensitive. Some of the ‘‘new’’
cases found at the incidence assessment would have been
prevalent cases of dementia had they received a prevalence
assessment, and therefore, are not classiﬁed as incident cases.
A weighted pseudo-likelihood approach to the parameters
of interest gives two maximum likelihood estimators that can
be combined to calculate the incidence. The ﬁrst estimator
calculates the probability of not having dementia at
the second wave, h^. This probability is calculated using all
individuals in the second wave assessments (both in A2 and
C2). The second estimator calculates the proportion of cases
of dementia at the second wave that already had dementia at
the ﬁrst wave, k^ (C2 only). This estimate is weighted to the
original study population seen at the prevalence wave in
order to represent those with dementia, but not assessed
during this wave. These estimates can be combined to give a
probability of being an incident case u^ ¼ ð1 h^Þð1 k^Þ and
then used to estimate the proportion of individuals with
incident dementia in the absence of dementia at the ﬁrst
wave i^ ¼ u^
u^þh^. An additional advantage of this method is that it
enables updates of the prevalence estimates using the new
two-year information [38].
Waves were planned to be 2 y apart, with time from
prevalence screen to prevalence assessment being one month.
The incidence rate is calculated as the proportion of
individuals who have incident dementia, i^, divided by the
mean time between waves (2 y) and presented as a rate per
1,000 person years. The 95% conﬁdence interval of the
incidence rates have been calculated by using 5,000 bias-
corrected and accelerated bootstrap samples [39].
Sensitivity Analysis
There are many different ways of approaching data in
incidence studies. Two sensitivity analyses are presented here
to investigate robustness.
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Complete diagnosis analysis. A sensitivity analysis was
carried out using only individuals who had two assessment
interviews, 2 y apart. Individuals originally not having
dementia at wave 1, but having it at wave 2 are ‘‘true’’
incident cases. This allows examination of bias in estimating
the proportion of individuals with dementia newly assessed at
wave 2 who were not assessed at prevalence. Using solely the
individuals with complete case information (the A0 and C2
group), incidence estimates can be calculated directly and
then back-weighted to the population at prevalence screen
(using the same method as in the original prevalence paper
[21]). This estimate is less precise than the method described
already because it is based on fewer individuals, but provides
information on bias and potential problems with the
modiﬁed incidence technique presented above.
Inclusion of mortality. Individuals with dementia are
known to be at greater risk of death than those without
dementia of the same age and sex [40]. Individuals lost to
follow-up due to death could therefore have been incident
dementia cases, and not included in our analysis. To examine
the impact this might have, a sensitivity analysis has been
conducted by combining the known rates of dementia with an
estimate in the literature of the excess of dementia seen in
deceased individuals. A relative risk of dementia in deceased
individuals of six in the 65–74 y age group, four in the 75–84 y
age group and two in the 85 y and above has been used [41].
The analysis has not been adjusted for dropout due to refusal,
as initial analysis of the dropout mechanisms shows no effect
of dementia on refusal rates, after adjusting for age, sex, and
cognitive ability [42]. The analysis here is already adjusted for
age and sex, and the weighting adjusts for cognitive ability.
Hospital and general practice records were not systemati-
cally reviewed across sites because pilot studies in MRC CFAS
Cambridgeshire showed that these are too inaccurate to act as
proxies of actual state. Recording of known dementia on
death certiﬁcates has been reported to be inaccurate in other
countries [43] and provisional analysis in MRC CFAS appears
to conﬁrm this (M. Dewey, personal communication).
Results
The Sample
The response rates at baseline ranged from 71% to 79%,
with 19% refusal rate. Figure 1 and Table 1 provide the audit
trail of the sample from prevalence screen to incidence
assessment (fuller details for each site are available on the
study Web site, http://www-cfas.medschl.cam.ac.uk). Attrition
through death and refusal can be seen to be the most
important reasons for loss to follow-up, with 32% lost to
follow-up; and key characteristics of those who drop out were
that they were more likely to be male, older, cognitively
impaired, functionally impaired, and living with others, with
less education and fairly poor self-perceived health (see
attrition paper for more details [42]). The sampling charac-
teristics of the study are shown in Table 2; most of the
incident cases arise from AGECAT 03þ and low or missing
MMSE groups, and these groups had very large sampling
fractions. The number of cases and a back-weighted estimate
of the total number of cases are also shown.
Incidence Data
In the complete study there were 20,165 person years of
follow-up of individuals at risk in the study, 8,233 in men, and
11,932 in women. In the individuals that survived and
returned for a follow-up interview at wave 2, there were
17,310 person years of follow-up of individuals at risk in the
study, 7,115 in men, and 10,195 in women. There were fewer
in the very old, with 355 person years at risk in the 90 y and
Table 1. Numbers Included in the First Two Waves of MRC CFAS, Version 6.2
Phase Group Cambridge Gwynedd Newcastle Nottingham Oxford Total
Prevalence Prevalence screen 2,601 2,625 2,524 2,514 2,740 13,004
Selected for prevalence assessment 579 (22) 795 (30) 687 (27) 699 (28) 797 (29) 3557 (27)
Died 7 (1) 10 (1) 10 (1) 19 (3) 26 (3) 72 (2)
Moved 1 (0) 3 (1) 8 (1) 1 (0) 1 (0) 14 (,1)
Refused 106 (18) 208 (26) 170 (25) 183 (26) 164 (21) 831 (23)
A0 done 465 (80) 574 (72) 499 (73) 496 (71) 606 (76) 2,640 (74)
Incidence Combined screen assessment eligible 465 (100) 574 (100) 499 (100) 496 (100) 606 (100) 2,640 (100)
Died 68 (14) 97 (17) 98 (19) 101 (20) 107 (17) 471 (17)
Moved 4 (1) 3 (1) 13 (3) 9 (2) 6 (1) 35 (1)
Refused 101 (22) 130 (23) 91 (18) 74 (15) 87 (14) 483 (18)
C2 done 292 (63) 344 (60) 297 (60) 312 (63) 406 (67) 1651 (63)
Incidence screen eligible 2,022 (78) 1,836 (70) 1,846 (73) 1,832 (73) 1,966 (72) 9,502b (73)
Died 203 (10) 153 (8) 157 (9) 174 (10) 144 (7) 831 (9)
Moved 22 (1) 30 (2) 27 (1) 26 (1) 29 (1) 134 (1)
Refused 369 (18) 294 (16) 252 (14) 211 (12) 236 (12) 1,362 (15)
S2 done 1,428 (71) 1,359 (74) 1,410 (76) 1,421 (78) 1,557 (79) 7,175 (76)
Selected for incidence assessmente 428 (30) 317 (23) 333 (24) 394 (28) 363 (23) 1,835 (26)
Died 6 (1) 3 (1) 9 (3) 7 (2) 11 (3) 36 (2)
Moved 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Refused 83 (19) 69 (22) 68 (20) 76 (19) 40 (11) 336 (18)
A2 done 339 (79) 245 (77) 256 (77) 311 (79) 312 (86) 1,463 (80)
Numbers that are bold and in parentheses are percentage of total; the remaining numbers in parentheses are percentage of subtotal.
aFifty-five individuals entered at this stage after temporarily refusing the prevalence assessment.
bA total of 9,502 eligible for incidence screen (the 9,447 not selected for prevalence assessment plus 55 who temporarily refused prevalence assessment).
DOI: 10.1371/journal.pmed.0020193.t001
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over age group. A total of 8,826 individuals were re-seen at
the wave 2 interviews who were initially in the ﬁrst wave
interview. Seven individuals not having dementia at preva-
lence were excluded because their dementia status at wave 2
was unknown, leaving 8,819 in the incidence analysis. There
were 136 individuals at C2 who had not previously received a
case-level diagnosis. In addition there were 212 cases
identiﬁed at A2 whose prevalent dementia status was
unknown. These ﬁgures when back-weighted to the total
sample equate to 774 cases at wave 2, of whom about 404
initially had dementia, giving an estimated 370 incident cases.
In checking case vignettes for possible misclassiﬁcation of
individuals with MMSE above standard cut points who were
diagnosed with incident dementia, we found 35 individuals
(out of 1,888) with MMSE at wave 2 above 21 (and 2 out of 895
with MMSE above 26) who had dementia at wave 2.
Centre Analysis
Incidence rates by centre are shown in Table 3 and Figure
2. The rates in each of the centres do differ as with
prevalence, but not in a systematic manner (meta-analysis
test for heterogeneity p ¼ 0.22).
Combined Incidence Analysis
Figure 3 shows the incidence rates per 1,000 person years
by age at prevalence screen and by sex, and Table 3 gives
more detail to the overall sex and age effects. Incidence
increases consistently with age for both men and women, and
the rates overall are similar for the two sexes. The population
burden of these rates equates to approximately 180,000 new
occurring dementia cases each year in England and Wales
(95% conﬁdence interval [CI], 105,000 to 325,000).
Sensitivity Analysis (Twice-Assessed Group)
Incidence rates calculated using the known incident cases
and back weighting to the prevalence screen population show
very similar rates. The conﬁdence intervals around these
estimates are wide (Table 3).
Sensitivity Analysis (Mortality Effect)
As expected, rates adjusted for a mortality effect are higher
than those without an adjustment, but only slightly. The
potential bias from the deceased individuals has the most
effect in men and on the estimate at age 75–79 y in which
both the death and dementia rate are rising. Of the 1,219
individuals that died between wave 1 and wave 2, 220 already
had dementia. Of the 750 with unknown dementia status
prior to death, the majority were in groups where the chances
of having prevalent dementia were clearly deﬁned (107 [14%]
with very high risk and 443 [59%] with very low risk). These
ﬁgures indicate that the choice of 2 y between waves
dramatically reduced the bias of dropout owing to death on
the incidence estimate.
Discussion
Summary of Findings
The MRC CFA Study provides the ﬁrst multi-site compar-
ison of incidence rates in ethnically homogeneous popula-
tions within a country and within Europe using identical
methodology. These are diverse sites with varying exposures
of potential importance in dementia [14]. As in the
prevalence study, no major differences were found across
the sites. Incidence does reﬂect prevalence despite the
variation in life expectancy across different regions in
England and Wales. Thus these estimates provide robust
estimates for the incidence of dementia in England and Wales
for age and sex for the ﬁrst time. They also provide robust
estimates using methods that can be repeated across time for
the investigation of cohort effects.
Gender effects were not found to be as marked as in many
other studies, with very similar rates between men and
women overall.
Incidence rates in both sexes rise very dramatically with
age, also reported in our formal risk analysis which showed an
odds ratio for the oldest versus youngest age groups of 23.6
Table 2. Numbers Assessed, Screened, Number of Actual Cases, and Back-Weighted Cases to Total Population by Sampling Strategy
and Centre–Only Individuals Seen at Both Prevalence and Incidence Phase
Cambridge Gwynedd Newcastle Nottingham Oxford
Phase Age Screening Test As/Sc Ca Bw As/Sc Ca Bw As/Sc Ca Bw As/Sc Ca Bw As/Sc Ca Bw
Prevalence 65–74 y AGECAT O3þ 12/12 5 5 5/6 5 6 13/13 5 5 14/15 6 6 11/11 8 8
MMSE ,21/missing 21/22 3 3 17/17 4 4 19/20 0 0 20/30 1 2 23/26 3 3
MMSE 21–25 48/167 0 0 79/138 1 2 57/107 0 0 55/97 1 2 88/156 3 5
MMSE 26–30 58/706 0 0 64/695 1 11 56/781 0 0 56/762 0 0 61/825 0 0
75þ y AGECAT O3þ 43/62 26 37 52/59 42 48 47/48 34 35 52/54 44 46 50/52 39 41
MMSE ,21/missing 44/92 8 16 38/67 5 9 29/53 4 7 30/66 5 11 62/109 16 28
MMSE 21–25 44/257 1 4 58/240 1 4 47/195 0 0 54/178 4 13 79/272 6 21
MMSE 26–30 20/400 0 0 30/480 1 16 27/488 0 0 30/530 0 0 31/511 0 0
Incidence 65–74 y AGECAT O3þ 17/18 15 16 19/20 13 14 13/13 11 11 25/27 22 24 16/18 13 15
(any assessment) MMSE ,21/missing 31/43 0 0 26/29 3 3 33/36 5 5 31/48 1 1 48/50 11 11
MMSE 21–25 113/185 0 0 96/175 1 2 89/141 2 3 95/138 5 7 118/178 3 4
MMSE 26–30 120/661 1 6 108/632 1 6 115/731 0 0 118/691 0 0 119/772 1 6
75þ y AGECAT O3þ 88/94 77 82 95/105 82 91 76/83 71 77 111/118 92 98 89/101 77 87
MMSE ,21/missing 90/113 18 22 105/124 9 10 66/82 13 16 85/109 16 21 138/157 35 40
MMSE 21–25 110/255 2 5 77/226 4 12 106/235 2 5 93/173 11 20 104/254 11 26
MMSE 26–30 60/349 1 7 62/391 0 0 53/384 0 0 63/428 1 11 80/432 0 0
As, numbers assessed; Bw, back-weighted cases to total population; Ca, number of actual cases; Sc, numbers screened.
DOI: 10.1371/journal.pmed.0020193.t002
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(90þ vs. 65–69 y, 95% CI, 10.5–53.0). There is no evidence of
the rates slowing in the oldest age groups, with sufﬁcient
person years at risk to provide robust estimates of rates up to
the age of 90 y.
Methodological Considerations
The sample. The samples followed here were geographi-
cally based, with reasonable response rates, similar or higher
than most other comparable studies, and known attrition;
and the base population was representative of the popula-
tions from which they were sampled including institutional-
ised respondents. This is in contrast to many dementia
studies that do not provide robust population estimates
because they either exclude institutionalised subjects or
cannot weight with conﬁdence for the local population.
Sample attrition. The greatest threat to the validity of the
Table 3. Number of Cases, Person Years, and Incidence Rate per 1,000 Person Years with 95% Confidence Interval
Group Subgroup Actual Number
of Casesa
Person Yearsb Main Analysis Sensitivity Analysis
Twice Assessed Only
Adjusted for Mortality
Ratec (95% CId) Ratec (95% CId) Ratec (95% CId)
Cambridge 114 3,582 20.7 (14.2–28.2) 29.0 (17.8–47.3) 29.2 (21.5–38.0)
Gwynedd 113 3,248 19.1 (12.3–29.3) 27.2 (14.9–51.6) 25.6 (17.6–35.2)
Centree Newcastle 104 3,401 15.6 (10.0–22.3) 15.5 (9.0–24.6) 22.5 (15.9–28.7)
Nottingham 148 3,379 19.3 (12.9–26.0) 20.5 (12.5–29.8) 27.0 (20.0–33.8)
Oxford 151 4,019 15.9 (10.6–23.7) 12.1 (7.1–18.3) 22.5 (16.7–30.4)
Agef 65–69 21 2,090 6.9 (3.3–14.5) 9.7 (3.2–36.1) 10.1 (5.1–16.8)
70–74 34 1,986 14.5 (7.4–34.1) 14.7 (6.3–44.0) 21.8 (13.4–34.9)
Men 75–79 42 1,626 14.2 (6.7–25.1) 14.3 (6.1–29.7) 27.7 (17.0–39.5)
80–84 47 1,031 17.0 (6.7–34.1) 23.6 (8.5–59.3) 37.6 (22.0–55.5)
85þ 52 435 58.4 (27.3–96.7) 45.7 (18.3–100.7) 66.4 (37.2–100.2)
Agef 65–69 19 2,388 6.3 (2.9–15.6) 10.1 (3.3–41.0) 8.2 (3.9–15.5)
70–74 28 2,586 6.1 (2.8–12.6) 8.7 (3.0–28.6) 7.9 (3.8–37.0)
Women 75–79 67 2,389 14.8 (8.5–25.1) 16.0 (8.7–27.3) 20.9 (13.4–29.7)
80–84 149 1,910 31.2 (21.2–34.1) 41.7 (24.5–80.6) 46.4 (34.1–60.8)
85þ 171 1,186 71.7 (52.0–96.7) 74.9 (46.1–110.0) 98.8 (76.3–121.7)
Agef 65–69 40 4,477 6.7 (3.8–12.4) 9.9 (4.5–23.4) 9.3 (5.6–14.2)
70–74 62 4,572 10.3 (6.2–19.9) 11.3 (5.9–25.2) 14.1 (9.6–22.0)
Total 75–79 109 4,016 14.5 (9.6–20.7) 15.3 (9.6–23.4) 23.7 (17.4–30.7)
80–84 196 2,942 26.5 (18.3–37.7) 37.1 (23.6–67.0) 43.3 (33.5–54.3)
85þ 223 1,621 68.5 (52.5–88.1) 68.1 (46.2–99.2) 91.3 (72.6–109.9)
aIncidence wave numbers not back-weighted to original population (both prevalent and incident cases in survivors).
bPerson years from prevalence wave to incidence wave in survivors.
cIncidence rate per 1,000 person years per year.
d95% Confidence interval calculated using 5,000 bias-corrected bootstrap samples.
eCentre rates standardised for population age distribution.
fAge (in years) at prevalence wave.
DOI: 10.1371/journal.pmed.0020193.t003
Figure 2. Centre Effects for the Three Different Incidence Models
DOI: 10.1371/journal.pmed.0020193.g002
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ﬁndings is the dropout experienced over the 2 y. This analysis
does not take interim interviews into account, or any further
sources of information, such as death certiﬁcates. However
these are unlikely to inﬂuence the estimates in a substantial
way, although they could reduce the variance seen. The
results do not adjust for attrition between waves due to
refusal, inability to contact, or moving from study area, which
possibly makes them conservative, due to cognitively im-
paired individuals having higher drop-out rates [42].
Interviewer bias across sites. Consistent bias in interviewer
ratings and responses across the sites could inﬂuence the
centre ﬁndings, but this was controlled for through the
national coordinator providing systematic training, regular
quality control and highly structured interviews.
Diagnosis. The diagnosis used here was based on the
AGECAT computerised algorithm [21]. The organicity sec-
tion of AGECAT was found to be sensitive to depression in
the screening interview, when used in isolation from the rest
of the instrument. In the assessment interview, it was more
stable and has shown good validity in a number of studies
conducted in a variety of settings [44,45]. Its main advantage
over standard clinical diagnosis is that interviews are
conducted by interviewers trained to achieve reliable ratings
on standardised items, which contribute to the computerised
algorithm, reducing the likelihood of systematic bias thus
providing consistency across sites and over time. Smaller
studies can afford clinical assessment and have often used
consensus diagnoses. These are extremely time consuming,
and no cost-effectiveness studies exist to compare a formal
standardised approach such as used here to provide evidence
for efﬁciency of methods put against some form of clinical
input. The one study published on GMS and AGECAT
methods suggests that the computerised algorithmic ap-
proach is no more variable when compared with clinical
consensus style assessments [46].
A small number of cases were diagnosed through clinical
review of the records, largely from the prevalence phase; as
explained in Methods, this was due to poverty of data rather
than clinical uncertainty. There is no guarantee of consis-
tency of consensus diagnosis over time, and thus the estimates
provided here, although perhaps less clinically attractive, are
robust enough for future comparison because the method-
ology is repeatable.
This analysis does not address clinical subtyping, but the
series of donations in the neuropathological component
from this study has provided the proportions of individuals
having dementia with different particular pathologies. This
analysis did reveal that Alzheimer-type pathology does
predominate in the age groups studied here, but also that
vascular disease is common and that both co-occur in most
individuals [47].
Sensitivity analysis. Many biases can be introduced in such
studies. Dropout and mortality are major reasons for
concern. In the analysis presented here, the possible effects
of mortality have been taken into account in the sensitivity
analysis and do not provide substantially different results.
Statistical methods. The methods used here were devel-
oped speciﬁcally for this study; they therefore take into
account the exact details of the study design. The methods
can be generalised to any study of a chronic disease with a
two-phase selection process. They are based however on
weighting methods deﬁned within strata; hence the use of
many groups (e.g., age, sex, and centre) would have too much
instability.
Implications of Findings
Many studies with similar two-phase, two wave designs
assume that those individuals who screen negative at baseline
could not have dementia (e.g., Rotterdam [1] and Paquid,
France [48,49]). In the MRC CFAS design, no such assumption
was made, with sampling for assessment interviews from
above the cut point. The analysis has taken into account, at
both prevalence and incidence waves, that a small proportion
of those above standard cut points (i.e., those who screen
negative) actually had dementia. Therefore this analysis has
fully adjusted for this type of error. It is reassuring that the
results obtained by this method are of the same order of
magnitude as in previously published studies, being broadly
Figure 3. Incidence Rates (and 95% Confidence Intervals) by Age and Sex
DOI: 10.1371/journal.pmed.0020193.g003
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comparable with the combined re-analyses conducted by
Jorm and Jolley [50]. The European combined analysis, which
does not include these data, but those from the sister site,
Liverpool, provides estimates that are also broadly similar;
however MRC CFAS gives the highest results of all the
studies. Figure 4 shows the comparison between the results
obtained from the Jorm and Jolley meta-analysis [50] and the
EURODEM group [20]. There is no marked heterogeneity
between the United Kingdom and other European sites. MRC
CFAS rates appear to be similar to those for the European
deﬁnition of mild dementia. The EURODEM exercise
provides almost identical estimates, apart from young age
groups. The slightly higher estimates do suggest that studies
that do not take all design features into account may slightly
underestimate their rates. Small differences, particularly in
the older ages, could give rise to large effects at a population
level and have major implications for policy makers, although
the differences at young ages could require changes in policy
and care provision.
Lack of a decline in incidence in extreme age suggests that
at the population level, there is not an extreme survivor effect
as has been suggested previously based on prevalence rates
[51]. This may be an artefact of the response rates, survival
effects, and nature of previous populations sampled in these
very old age groups. Although the combined analyses of
incidence studies suggest that there is a gender effect, this is
not found here. The male increase in life expectancy is likely
therefore to be accompanied by substantial increases in the
numbers of incident dementia in men as the average life
expectancy moves towards the age at which the rates increase
dramatically [52].
The methods used within this paper can be applied to any
study of dementia, whether longitudinal or two-phase, as long
as some form of follow-up has been attempted on everyone.
The results do not assume that the individuals who screen
negative do not have dementia, and are not sensitive to
weighting assumptions in this analysis.
Although many risk factors have been described for
dementia and Alzheimer’s disease, there is no evidence within
England and Wales that variation at the population level in
these risk factors inﬂuences incidence in the population.
There is no evidence of tailing off in the incidence rates for
dementia in the oldest age groups, contrasting with previous
suggestions in the literature that rates might be lower in the
oldest age groups [51]. These ﬁndings have considerable
implications for future planning nationally and internation-
ally in the context of global ageing.
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Patient Summary
Background Dementia remains a condition without a cure. Dementia is
defined as a progressive deterioration in cognitive abilities that interfere
with ability to function independently. It is more common among older
people, and a big health problem in aging societies. When describing
how common dementia is, scientists use two measurements: the
prevalence, meaning how many people have dementia at a particular
time point or within a particular time period; and the incidence, meaning
the number of new cases in a particular time period.
Why Was This Study Done? Even though dementia is a big public
health issue, we do not have good comparative data on its incidence or
prevalence. This is mostly because different studies have used different
definitions for dementia and different methods to collect data, and are
thus not suitable for accurate comparisons. The British Medical Research
Council funded this study to get data on dementia in the United
Kingdom that were suitable to compare dementia incidence between
men and women, different age groups, different locations, etc.
What Did the Researchers Do and Find? The researchers studied
dementia incidence in individuals from five different sites in England and
Wales, two in rural areas and three in cities. In all sites, they studied over
1,000 people each from two age groups: between 65 and 74 y, and 75 y
and over. They found that incidence rises with age among both men and
women, and that this rise continues in the oldest age groups. There were
no differences between the five sites.
What Does This Mean? It seems that known differences in risk factors
between some of the sites did not have a great effect. Likewise, this
careful analysis did not reveal differences between men and women that
had been suggested by other studies. Another previous suggestion,
namely that incidence might fall again in the oldest age groups, was also
not confirmed by the data here. The results will be important for future
health care planning within the United Kingdom and in other countries
with rapidly aging populations.
Where Can I Find More Information Online? The following Web sites
have relevant information.
The home page of the Medical Research Council Cognitive Function and
Ageing Study:
http://www-cfas.medschl.cam.ac.uk/
MedlinePlus on dementia:
http://www.nlm.nih.gov/medlineplus/dementia.html
The American Geriatrics Society’s Foundation for Health in Aging (search
for dementia):
http://www.healthinaging.org/about/
The Alzheimer’s Society (United Kingdom):
http://www.alzheimers.org.uk/
Alzheimer’s Disease International (an international federation of national
Alzheimer Associations):
http://www.alz.co.uk
Alzheimer’s Association (United States):
http://www.alz.org/
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